Meningococcal serogroup B vaccines: Will they live up to expectations?

Expert Review of Vaccines

Volumn 10, Issue 5, 2011, Pages 559-561

  Zollinger, Wendell D ^a   Poolman, Jan T ^b   Maiden, Martin C J ^c  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

antigenic variation; factor H binding protein; fHbp; MenB; OMV; outer membrane vesicle; PorA; Porin A

Indexed keywords

BACTERIAL PROTEIN; COMPLEMENT FACTOR H; GNA 1030; GNA 1870; GNA 2091; LIPOOLIGOSACCHARIDE; LP 2086; MEMBRANE PROTEIN; MENINGOCOCCAL SEROGROUP B VACCINE; MENINGOCOCCUS VACCINE; NEISSERIAL ADHESIN A PROTEIN; OUTER MEMBRANE VESICLE VACCINE; UNCLASSIFIED DRUG;

BACTERIAL STRAIN; CELL VACUOLE; CROSS REACTION; DRUG FORMULATION; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANTIGENS, BACTERIAL; CROSS PROTECTION; GENETIC VARIATION; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; POLYSACCHARIDES, BACTERIAL;

EID: 79957593944     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.41     Document Type: Review

References (21)

1. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA 103, 10834-10839 (2006). (Pubitemid 44148381)
2. Wong SH, Lennon DR, Jackson CM et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr. Infect. Dis. J. 28, 385-390 (2009).
3. Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 28, 2122-2129 (2010).
4. Findlow J, Borrow R, Snape MD et al. Multicenter, open-label, randomized Phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51, 1127-1137 (2010).
5. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27, 2794-2803 (2009).
6. Snape MD, Dawson T, Oster P et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J. 29, e71-e79 (2010).
7. Frasch CE, Zollinger WD, Poolman JT. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev. Infect. Dis. 7, 504-510 (1985).
8. Jolley KA, Brehony C, Maiden MCJ. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol. Rev. 31, 89-96 (2007). (Pubitemid 46058824)
9. Bai X, Borrow R. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Expert Rev. Vaccines 9, 1203-1217 (2010).
10. Bjune G, Høiby EA, Grønnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093-1096 (1991).
11. Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14, 195-207; discussion 208-210 (1991).
12. Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281, 1520-1527 (1999). (Pubitemid 29200936)
13. Saukkonen K, Leinonen M, Abdillahi H, Poolman JT. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 7, 325-328 (1989). (Pubitemid 19215713)
14. Boutriau D, Poolman J, Borrow R, F et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vaccine Immunol. 14, 65-73 (2007).
15. Cartwright K, Morris R, Rümke H et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17, 2612-2619 (1999). (Pubitemid 29314456)
16. Urwin R, Russell JE, Thompson EAL, Holmes EC, Feavers IM, Maiden MCJ. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect. Immun. 72, 5955-5962 (2004). (Pubitemid 39303710)
17. Pettersson A, Kuipers B, Pelzer M et al. Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific. Infect. Immun. 58, 3036-3041 (1990). (Pubitemid 20267700)
18. Koeberling O, Giuntini S, Seubert A, Granoff DM. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin. Vaccine Immunol. 16, 156-162 (2009).
19. Keiser PB, Biggs-Cicatelli S, Moran EE et al. A Phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29, 1413-1420 (2011).
20. van de Waterbeemd B, Streefland M, van der Ley P et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 28, 4810-4816 (2010).
21. Weynants VE, Feron CM, Goraj KK et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect. Immun. 75, 5434-5442 (2007). (Pubitemid 350033632)